Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-05-18
DOI
https://doi.org/10.1056/nejmoa2414108
Citations
99
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
150.32
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

Justin M. Oldham, Daniel Wachtlin, Vincent Cottin, Luca Richeldi et al.
99 citations
New England Journal of Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
150.32
article

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

Justin M. Oldham, Daniel Wachtlin, Vincent Cottin, Luca Richeldi, Marlies Wijsenbeek, Arata Azuma, Toby M. Maher, Claudia Valenzuela, Maud Gordat, Donald F. Zoz, Christina Schlecker, Susanne Stowasser, Yi Liu, Emmanuelle Clerisme-Beaty, Fernando J. Martinez, Michael Kreuter
article en
99 citations

Abstract

In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).

New England Journal of MedicineVol. 392(22)
Université Claude Bernard Lyon 1 (FR), Università Cattolica del Sacro Cuore (IT), University of Southern California (US), UMass Memorial Health Care (US), Boehringer Ingelheim (Germany) (DE), University of Massachusetts Chan Medical School (US), Johannes Gutenberg University Mainz (DE), University of Michigan (US), Erasmus MC (NL), University Medical Center of the Johannes Gutenberg University Mainz (DE), Hospices Civils de Lyon (FR), Lung Institute (US), Memorial Health System (US), Hospital Universitario de La Princesa (ES), Hôpital Louis Pradel (FR), Boehringer Ingelheim (France) (FR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Boehringer Ingelheim (United States) (US), Imperial College London (GB), Universidad Autónoma de Madrid (ES), Nippon Medical School (JP)
Openalex Percentile: Top 0%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
150.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.